Cloud-clone
SKU:MAB215Hu22
Monoclonal Antibody to Fibrinogen Beta Chain (FGB)
Monoclonal Antibody to Fibrinogen Beta Chain (FGB)
Couldn't load pickup availability
;Immunohistochemistry: 5-20µg/mL;
;Immunocytochemistry: 5-20µg/mL;
;Optimal working dilutions must be determined by end user.
Product No.
MAB215Hu22
Organism Species
Homo sapiens (Human).
Source
Monoclonal antibody preparation
Host
Mouse
Potency (Clone Number)
2#
Ig Isotype
IgG2b Kappa
Purification
Protein A + Protein G affinity chromatography
Label
None
Immunogen
RPB215Hu01-Recombinant Fibrinogen Beta Chain (FGB)
Buffer Formulation
0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
Traits
Liquid
Concentration
1mg/ml
Organism Species More
n/a
Applications
WB; IHC
If the antibody is used in flow cytometry, please check FCM antibodies.
UOM
20µl 100µl 200µl 1ml 10ml
SPECIFITY
The antibody is a mouse monoclonal antibody raised against FGB. It has been selected for its ability to recognize FGB in immunohistochemical staining and western blotting.
USAGE
Western blotting: 0.01-2µg/mL;
Immunohistochemistry: 5-20µg/mL;
Optimal working dilutions must be determined by end user.
STORAGE
Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
| Magazine | Citations |
| United States Patent Application | Compositions and Methods for Diagnosing Lung Cancer y2016:0077095.html |
| Microbial Pathogenesis | Crystal structure of GAPDH of Streptococcus agalactiae and characterization of its interaction with extracellular matrix molecules Pubmed: 30553015 |
| GLYCOCONJUGATE JOURNAL | Nattokinase-heparin exhibits beneficial efficacy and safety—an optimal strategy for CKD patients on hemodialysis Pubmed: 30788657 |
Share
